248 related articles for article (PubMed ID: 9051250)
1. Intermediate-dose busulfan and cyclophosphamide as a conditioning regimen for bone marrow transplantation in a case of Fanconi anemia in myelodysplastic transformation.
Maschan AA; Kryzanovskii OI; Yourlova MI; Skorobogatova EV; Pashanov ED; Potapova YE; Timonova LA; Bogatcheva NY; Samochatova EV; Roumjantzev AG
Bone Marrow Transplant; 1997 Feb; 19(4):385-7. PubMed ID: 9051250
[TBL] [Abstract][Full Text] [Related]
2. Bone marrow transplantation from matched related donors for patients with Fanconi anemia using low-dose busulfan and cyclophosphamide as conditioning.
Torjemane L; Ladeb S; Ben Othman T; Abdelkefi A; Lakhal A; Ben Abdeladhim A
Pediatr Blood Cancer; 2006 Apr; 46(4):496-500. PubMed ID: 16333862
[TBL] [Abstract][Full Text] [Related]
3. Busulfan, cyclophosphamide and melphalan as conditioning regimen for bone marrow transplantation in children with myelodysplastic syndromes.
Locatelli F; Pession A; Bonetti F; Maserati E; Prete L; Pedrazzoli P; Zecca M; Prete A; Paolucci P; Cazzola M
Leukemia; 1994 May; 8(5):844-9. PubMed ID: 8182940
[TBL] [Abstract][Full Text] [Related]
4. A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome.
Kröger N; Schetelig J; Zabelina T; Krüger W; Renges H; Stute N; Schrum J; Kabisch H; Siegert W; Zander AR
Bone Marrow Transplant; 2001 Oct; 28(7):643-7. PubMed ID: 11704786
[TBL] [Abstract][Full Text] [Related]
5. Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia.
Bibawi S; Abi-Said D; Fayad L; Anderlini P; Ueno NT; Mehra R; Khouri I; Giralt S; Gajewski J; Donato M; Claxton D; Braunschweig I; van Besien K; Andreeff M; Andersson BS; Estey EH; Champlin R; Przepiorka D
Am J Hematol; 2001 Aug; 67(4):227-33. PubMed ID: 11443634
[TBL] [Abstract][Full Text] [Related]
6. Unrelated donor bone marrow transplantation for Fanconi anemia.
Davies SM; Khan S; Wagner JE; Arthur DC; Auerbach AD; Ramsay NK; Weisdorf DJ
Bone Marrow Transplant; 1996 Jan; 17(1):43-7. PubMed ID: 8673053
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR;
Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
[TBL] [Abstract][Full Text] [Related]
8. Fludarabine, low-dose busulfan and antithymocyte globulin as conditioning for Fanconi anemia patients receiving bone marrow transplantation from HLA-compatible related donors.
Maschan AA; Trakhtman PE; Balashov DN; Shipicina IP; Skorobogatova EV; Skvortsova YV; Dyshlevaja ZM; Samochatova EV; Rumiantsev AG
Bone Marrow Transplant; 2004 Aug; 34(4):305-7. PubMed ID: 15195080
[TBL] [Abstract][Full Text] [Related]
9. [Bone marrow re-transplantation following a busulfan and cyclophosphamide regimen].
Hirasawa A; Hiruma K; Wakita H; Endo N; Takabayashi K; Oh H; Yoshida S; Aotsuka N; Asai T; Igarashi T
Rinsho Ketsueki; 1990 Jul; 31(7):974-8. PubMed ID: 2214194
[TBL] [Abstract][Full Text] [Related]
10. Modified conditioning regimen busulfan-cyclophosphamide followed by allogeneic stem cell transplantation in patients with multiple myeloma.
Zhang XH; Huang XJ; Liu KY; Xu LP; Liu DH; Chen H; Chen YH; Wang JZ; Han W; Lu DP
Chin Med J (Engl); 2007 Mar; 120(6):463-8. PubMed ID: 17439737
[TBL] [Abstract][Full Text] [Related]
11. Bone marrow transplantation for patients with Fanconi anemia: reduced doses of cyclophosphamide without irradiation as conditioning.
Medeiros C; Zanis-Neto J; Pasquini R
Bone Marrow Transplant; 1999 Oct; 24(8):849-52. PubMed ID: 10516695
[TBL] [Abstract][Full Text] [Related]
12. Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens.
Bleyzac N; Souillet G; Magron P; Janoly A; Martin P; Bertrand Y; Galambrun C; Dai Q; Maire P; Jelliffe RW; Aulagner G
Bone Marrow Transplant; 2001 Oct; 28(8):743-51. PubMed ID: 11781625
[TBL] [Abstract][Full Text] [Related]
13. Intensified conditioning regimen with busulfan followed by allogeneic BMT in children with myelodysplastic syndromes.
Rubie H; Attal M; Demur C; Brousset P; Duchayne E; Rigal-Huguet F; Dastugue N; Robert A
Bone Marrow Transplant; 1994 Jun; 13(6):759-62. PubMed ID: 7920311
[TBL] [Abstract][Full Text] [Related]
14. Bone marrow transplantation from matched siblings in patients with fanconi anemia utilizing low-dose cyclophosphamide, thoracoabdominal radiation and antithymocyte globulin.
Ayas M; Solh H; Mustafa MM; Al-Mahr M; Al-Fawaz I; Al-Jefri A; Shalaby L; Al-Nasser A; Al-Sedairy R
Bone Marrow Transplant; 2001 Jan; 27(2):139-43. PubMed ID: 11281382
[TBL] [Abstract][Full Text] [Related]
15. A fludarabine-based protocol for bone marrow transplantation in Fanconi's anemia.
Kapelushnik J; Or R; Slavin S; Nagler A
Bone Marrow Transplant; 1997 Dec; 20(12):1109-10. PubMed ID: 9466288
[TBL] [Abstract][Full Text] [Related]
16. Unrelated donor bone marrow transplantation in Fanconi anaemia: the Leiden experience.
Zwaan CM; Van Weel-Sipman MH; Fibbe WE; Oudshoorn M; Vossen JM
Bone Marrow Transplant; 1998 Mar; 21(5):447-53. PubMed ID: 9535036
[TBL] [Abstract][Full Text] [Related]
17. Donor lymphocyte infusions for post-transplant relapse of refractory anemia with excess blasts and monosomy 7.
Skinner R; Velangi M; Bown N
Pediatr Blood Cancer; 2008 Mar; 50(3):670-2. PubMed ID: 17253642
[TBL] [Abstract][Full Text] [Related]
18. Successful allogeneic bone marrow transplantation in a case with myelodysplastic syndrome which developed following Fanconi anemia.
Ikushima S; Hibi S; Todo S; Sawada T; Matsumoto Y; Iwami H; Tsunamoto K; Kasubuchi Y; Yabe M; Kato S
Bone Marrow Transplant; 1995 Oct; 16(4):621-4. PubMed ID: 8528182
[TBL] [Abstract][Full Text] [Related]
19. High-dose busulfan and cyclophosphamide are an effective conditioning regimen for allogeneic bone marrow transplantation in chemosensitive multiple myeloma.
Cavo M; Bandini G; Benni M; Gozzetti A; Ronconi S; Rosti G; Zamagni E; Lemoli RM; Bonini A; Belardinelli A; Motta MR; Rizzi S; Tura S
Bone Marrow Transplant; 1998 Jul; 22(1):27-32. PubMed ID: 9678792
[TBL] [Abstract][Full Text] [Related]
20. Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia.
Kröger N; Zabelina T; Sonnenberg S; Krüger W; Renges H; Stute N; Finkenstein F; Mayer U; Holstein K; Fiedler W; Colberg H; Sonnen R; Kuse R; Braumann D; Metzner B; del Valle F; Erttmann R; Kabisch H; Zander AR
Bone Marrow Transplant; 2000 Oct; 26(7):711-6. PubMed ID: 11042650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
